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Thereisevidence thattheprinciplespresentinthewidelyconsumedIndianfoodplantC.ﬁmbriataextract (CFE)suppressappetite,
and provide antiobesogenic and metabolic beneﬁts. The Diet-Induced Obesity (DIO) rat model was used to investigate CFE’s
anorexigenic eﬀects. Rats were randomly divided into three groups: (i) untreated control (C), (ii) control for cafeteria diet (CA),
and (iii) cafeteria diet fed + CFE treated. Rats in the test group received cafeteria diet and CFE from day one onwards. CFE
was administered by gavage at three doses (25, 50, 100mg/KgBW per day) for 90 days. The antiobesogenic eﬀects of CFE were
evaluatedby monitoringchangesinfeedintake,body weight,serumlipidandhormonal(leptin) proﬁles,fatpads,andliverweight.
Antiatherosclerotic eﬀects were measured by histology. CFE induced signiﬁcant and dose-dependent inhibition of food intake,
with dose-related prevention of gains in body weight, liver weight, and fat pad mass. Alterations in serum lipid proﬁles associated
with weight gain were similarly inhibited, as were the typical increases in serum leptin levels. These data substantiate CFE’s
reported anorexigenic eﬀects. CFE treatment also conferred protection against atherogenesis. We conclude that CFE possesses
antiobesogenic and antiatherosclerotic properties.
1.Introduction
Obesity is increasingly prevalent. Cheap, calorie-dense foods
and relatively inactive lifestyles create long-term imbalances
betweenenergyuptakeandexpenditure,leadingtoadipocyte
hypertrophy and subsequently hyperplasia. Excess adipose
tissue functions as an endocrine organ, producing bioactive
molecules such as Il-6, TNF-alpha, and PAF-1 which are
implicated in many disease states including diabetes and
atherosclerosis. It also produces the peptide hormone lep-
tin, which transmits a satiety signal to the hypothalamus
and acts as a negative feedback loop of the lipostat [1].
Leptin eﬀects on food intake and neuroendocrine functions
involve intermediate hypothalamic neuropeptides such as
proopiomelanocortin (POMC) and neuropeptide-Y (NPY)
in the hypothalamus which regulate appetite, energy expen-
diture, and sympathetic nervous system outﬂow [1–3]. In
obesity, the commonly found high leptin levels are not
associated with appetite suppression, giving rise to the
concept of central leptin resistance or insensitivity [4, 5].
This resistance may be caused by mutations aﬀecting leptin
transport, receptor aﬃnity, or signal transduction. The
majority of cases, however, probably reﬂect physiological de-
sensitisation caused by excessive adipose tissue and leptin
levels [6]. Restoring leptin sensitivity and hypothalamic
appetite control presents an exciting new target in obesity
management.
Pharmaceutical approaches are still in their early stages.
The pregnane glycosides in Hoodia [7] exert appetite-
suppressant eﬀects via enhanced hypothalamic signaling [8],2 Journal of Nutrition and Metabolism
but this plant risks extinction. We studied Caralluma ﬁm-
briata, a traditional Indian “famine food” with no history
of adverse eﬀects, which also contains pregnane glycosides
[9]. This study evaluated the extract of C. ﬁmbriata (CFE,
Slimaluma.) for appetite suppressing, antiobesogenic and
antiatherogenic properties in the DIO rat model.
2.Materialsand Methods
2.1. Animals and Housing. Male Wistar rats (200–220g),
bred from a stock obtained from the Central Animal Facility,
IndianInstituteofScience,Bangalore,India, wereusedin the
study. Animals were housed individually in polypropylene
cagesfor atleast 1 week ofacclimation beforethe experiment
started. Animals were cared for in accordance with the
principles of animal ethics guidelines, and the study was
approved by the Institutional Animal Ethics Committee
(IAEC). The rats were maintained under standard labora-
tory conditions at a room temperature at 23 ± 1◦Cw i t h
relative humidity: 50 ± 10% and 12h light/dark cycle. All
experiments were conducted under strictly controlled and
pathogen-free conditions.
2.2. Procedures. The C. ﬁmbriata extract (CFE) was prepared
andgiftedbyGreenChem,Bangalore,India.ToproduceCFE,
the aerial parts of the plant were extracted with alcohol to
obtain a 25% solution of pregnane glycosides, which was
lyophilized to powder.
2.3. Experimental Design. The animals were randomly
divided into three groups (N = 6): (i) untreated control,
(ii) control for cafeteria diet (CA), and (iii) cafeteria diet
fed + CFE treated. Rats in the untreated control group were
fed standard pellet chow ad libitum, while rats in the CA
and CA + CFE treatment groups received both pellet chow
and cafeteria diet. CFE was administered by gavage, at three
diﬀerent doses, 25, 50, 100mg/kg/day, for 90 days.
2.4. Diet-Induced Obesity (DIO). Obesity was induced by
providing modiﬁed versions of the Harris (1993) high-fat
cafeteria diet [10]. It consisted of 3 variants: (i) condensed
milk + bread + peanuts + pellet chow (4:1:4:1), (ii) choco-
late + biscuits + dried coconut + pellet chow (3:2:4:1),
and (iii) cheese + boiled potatoes + beef tallow + pellet
chow(4:2:4:1).Thediﬀerent variants were presented on
alternate days throughout the treatment period.
2.5. Indirect Antiappetite Assay. Group (iii) animals received
cafeteria diet and CFE from day one. Daily food consump-
tionwasdeterminedbyweighingfeedclearance.Theappetite
suppressing activity of CFE was calculated by monitoring (a)
food intake for 90 days, (b) animal’s bodyweight at baseline,
weeklyand atterm,and(c)theweightsoffatpads(perirenal,
mesenteric, and,epididymal) and liver at term.
2.6. Analysis of Serum Obesity Indicators. Serum obesity
indicators including cholesterol (TC), triglycerides (TG),
and high-density lipoprotein (HDL) were measured using
a commercial kit (Span Diagnostic Ltd, India) in semiau-
tomatic analyzer (Micro Lab-200). Low-density lipoprotein
(LDL) and very low-density lipoprotein (VLDL) levels were
calculated adopting the prescribed formula.
2.7.Analysis ofSerumLeptin. Atterm,bloodwascollectedby
cardiac puncture under mild sodium pentothal anesthesia;
the serum was separated and stored at −20◦C until analysis.
Leptin was determined using a commercial rat Enzyme-
Linked Immunosorbent Assay (ELISA) kit (BioVendor,
Czech Republic).
2.8. Antiatherosclerosis Study. Animals were initially per-
fused with saline. Sections of aorta from aortic arch to
thoracic aorta were removed and ﬁxed in 10% formalin
neutrally buﬀered solution. 3mm segments taken at 5mm
distance from the bifurcation of the left subclavian artery
were embedded in paraﬃnw a x .5 μm thick cross-sections
were cut and stained with hematoxylin and eosin to deter-
mine intimal thickening.
2.9. Data Analysis. All the values were expressed as the
mean ± SEM and analyzed by one-way analysis of variance
(ANOVA) using the Brown-Forsythe statistic followed by
Games-Howell post hoc comparisons tests in order to test
diﬀerences between groups. These options were chosen as
they do not require any assumptions of homogeneity of
variance. The level of statistical signiﬁcance was set at P<
.05.The statisticalanalyses were runusing SPSSforWindows
(version 16, Chicago, IL).
3.Results
3.1. Feeding Behavior. Feeding behavior was monitored in
the test animals for 90 days (Figure 1). As expected, food
intake was signiﬁcantly greater in CA-fed groups than
in the group given pellet chow (P<. 05). Concurrent
administration of 25, 50, and 100mg/kg/day of CFE with
CA reduced food intake considerably compared to both CA
and pellet chow groups (P<. 05). Both the degree and time
course of the reduction in food intake were dose dependent.
The anorexigenic eﬀects of the lowest dose (25mg/day) were
apparent by the end of week 7 (P<. 05), the intermediate
dose (50mg/kg/day) emerged by the end of week 4, and the
eﬀects of the highest dose (100mg/kg/day) emerged were
already evident at the beginning of the third week.
3.2. Body Weight. Animals in the untreated control group
increased body weight by 147.50% (297.66 ± 2.78g) at the
end of the experiment (Figure 2). Those in the CA group
increased weight by 172.30% (350.34 ± 2.13g), signiﬁcantly
more than the untreated control (P<. 05). Rats in all three
CA + CFE groups gained weight at or close to the lower
rate of the untreated control group. There was a hint of a
dose-response curve. Weight gain in the CA + 25mg/kg/day
CFE group was 142.46% (312.12 ± 3.21g), CA +
50mg/kg/day CFE group was 136.53% (291.25 ± 3.11g),
and CA + 100mg/kg/day CFE group brought to 136.00%Journal of Nutrition and Metabolism 3
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Figure 1: Feed intake in grams over 90 days.
(288.50±2.11g).Theseweightgains wereallsigniﬁcantlyless
than the CA-fed animals (P<. 05, Figure 1). 5 0m g / k g / d a y
of CFE appears to be the optimal antiobesogenic dose.
Table 1 shows that administration of the CA diet
signiﬁcantly increased the weight of perirenal (P = .0001),
epididymal (P = .0001),and mesenteric fat pads(P = .0001)
compared to the animals fed pellet chow. In animals fed
CA+CFE, weight gain in all fat pads was considerably lower
than in the CA group, with the 50 and 100mg/kg/day doses
giving results close to the untreated control group. The CA
diet resulted in fatty liver and increased the liver mass by
132.66% compared to the untreated animals (P<. 0001).
In rats given CA + CFE, liver weight gain was reduced in
a dose-related manner. At 25mg/kg/day CFE, liver weight
was reduced eﬀectively to the untreated control value, that
is, 105.14%. At 50mg/kg/day CFE, liver weight was below
theuntreated control value,at 78.57%,and at100mg/kg/day
CFE liver weight was reduced to 75.14%. The reduced liver
weight in the two higher-dose groups reﬂects the reduced
caloriﬁc intake and reduced body weight gain at these doses;
there were no signs of hepatotoxicity.
3.2.1. Serum Obesity Indicators. The cafeteria diet produced
the predicted changes in all serum obesity indicators, all of
which were positively modiﬁed by CFE in a generally dose-
dependent manner, as indicated in Table 2.
Table 2 shows that total cholesterol in the CA group
increased by 125.90% (74.78 ± 0.46mg/dL) compared to
untreated controls (P<. 0001). Coadministration of CFE
at 25mg/kg/day had comparatively little eﬀect (119.26%;
89.19 ± 1.61; P = .001); at 50mg/kg/day the increase
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Figure2:Eﬀect ofCFEonrats’body weightingramsover12weeks.
was restricted to 110.79% (82.86 ± 1.73; P = .025); at
100mg/kg/day total cholesterol was eﬀectively normalized,
at 102.01% (76.30 ± 1.29) with no statistical diﬀerences
between this group and the controls (P = .797). Serum
triglycerides in the CA group increased by 207.76% (150.9 ±
1.61) compared to untreated controls (P<. 0001). Coad-
ministration of25,50,and100mg/kg/dayCFErestricted this
increase to 161.59% (117.30 ± 0.92; P = .0001), 149.29%
(108.36 ± 1.51; P = .0001), and 132.08% (95.9 ± 0.75; P =
.0001), respectively.
LDL levels in the CA group were signiﬁcantly increased
compared to untreated controls (P = .0001). While coad-
ministration of 25mg/kg/day CFE did not have a statistically
signiﬁcant impact; 50 (P = .0001) and 100mg/kg/day CFE
(P = .0001) eﬀectively prevented any increase in LDL levels.
Serum HDL levels fell in the CA group compared
to untreated controls (P = .0001). Coadministration of
50mg/kg/day CFE progressively reduced the fall in HDL
levels (P = .001), while 100mg/kg/day CFE eﬀectively
prevented any decline in HDL levels (P = .0001).
VLDL levels were signiﬁcantly elevated in CA-fed rats
compared totheuntreated controls (P = .0001).Coadminis-
tration of 25 (P = .001), 50 (P = .0001), and 100mg/kg/day
(P = .0001) CFE signiﬁcantly inhibited this increase in a
dose-dependent manner.
3.3. Serum Leptin Concentrations. Table 2 also shows that
in the CA group, the serum leptin concentration was
dramatically higher than in untreated animals (P = .0001).
Concurrent administration of CFE eﬀectively prevented this
increase (P = .0001) at all doses.4 Journal of Nutrition and Metabolism
Table 1: Morphometric analyses of fat pads and liver weight.
Weight in grams Mean values Browne-Forsyth Sig.
Untreated control Cafeteria 25mg CFE 50mg CFE 100mg CFE
(SEM) (SEM) (SEM) (SEM) (SEM)
Perirenal 3.36 (±0.11) 11.33 (±0.38) 6.29 (±0.59) 4.83 (±0.21) 3.85 (±0.21) 88.42 0.0001
Epididymal 2.13 (±0.11) 6.4 (±0.38) 4.5 (±0.59) 3.4 (±0.21) 3.9 (±0.21) 51.1 0.0001
Mesenteric 3.52 (±0.17) 6.76 (±0.22) 4.35 (±0.13) 3.18 (±0.24) 2.83 (±0.16) 71.2 0.0001
Liver 10.5 (±0.31) 13.9 (±0.27) 11.04 (±0.36) 8.26 (±0.18) 7.9 (±0.21) 79.3 0.0001
N in each group 6 6 6 6 6
Table 2: Obesity indicators and impact of CFE.
Weight in grams Mean values Browne-Forsyth Sig.
Untreated control Cafeteria 25mg CFE 50mg CFE 100mg CFE
(SEM) (SEM) (SEM) (SEM) (SEM)
Serum lipids
Cholesterol 74.78 (±0.46) 94.16 (±0.48) 89.20(±1.61) 82.86 (±1.73) 76.30 (±1.29) 44.63 0.0001
Triglyceride 72.6 (±0.98) 150.9 (±1.61) 117.3(±0.93) 108.36 (±1.51) 95.9 (±0.75) 568.74 0.0001
LDL 18.89 (±1.02) 36.5 (±1.40) 35.54(±1.02) 20.37 (±0.79) 14.28 (±1.08) 88.8 0.0001
HDL 42.8 (±1.92) 25.62 (±1.78) 25.5(±2.3) 40.9 (±0.64) 43.0 (±0.74) 32.15 0.0001
VLDL 13.15 (±0.60) 33.02 (±1.19) 23.57(±0.8) 21.62 (±0.93) 19.62 (±1.1) 58.01 0.0001
Serum leptin 1.65 (±0.17) 13.9 (±0.68) 3.40 (±0.11) 1.92 (±0.20) 1.63 (±0.27) 1237.7 0.0001
N in each group 6 6 6 6 6
3.4. Atheroma Formation. Atheroma formation is the hall-
mark feature in the development of clinical atherosclerosis.
Figure 3(a) shows a section of healthy aorta taken from a rat
fed on lab chow. Feeding rats a cafeteria diet with high fat
content caused deposition of lipids in the intimal region of
the aortic arch, as shown in Figure 3(b). Treating rats con-
currently with diﬀerent doses of CFE completely prevented
lipid deposition and restored normal aortic characteristics as
shown in Figure 3(c) which is representative of all three CFE
groups.
4.Discussion
Feeding rats a cafeteria, high-fat diet inevitably causes
hyperphagia resulting in increased body weight compared
to pellet chow fed animals and is a widely accepted model
for clinical obesity. This gain in body weight is largely
due to increased fat mass as a result of preadipocyte
proliferation and diﬀerentiation and, to an extent, accu-
mulation of lipids in the liver [11, 12]. Our results
demonstrate that CFE has pronounced dose-dependent
appetite suppressant and antiobesogenic eﬀects in this
model. These eﬀects were reﬂected in the feed intake,
body weight, liver weight, fat pad mass, and serum lipid
proﬁles of the rats in our various treatment groups. The
hyperleptinaemia and implicit leptin resistance character-
istics of obesity were abolished by CFE. Fiftymg/kg/day
of CFE appears to be the optimal dose for prevent-
ing CA diet-induced changes in body weight, hormones,
fat pads, and liver. Kidney and liver function data were
assayed at all probe points. Slight negative changes in
liver and kidney function induced by the cafeteria diet
were reduced by CFE in a dose-dependent manner and
approached normal values at the intermediate dose level.
The null ﬁndings are not detailed here; two clinical trials
of the food extract CFE also found no adverse eﬀects
[13, 14].
We believe that CFE may act via multiple mechanisms.
The decline in food intake may reﬂect direct intervention
in appetite control at the level of the hypothalamus, where
t h ep r e g n a n eg l y c o s i d e sa r ek n o w nt oa c t[ 8]. There is
also evidence that the pregnane glycosides act directly on
adipose tissue, by inhibiting adipocyte proliferation and
diﬀerentiation [15–17]. An alternative hypothesis is that
CFE may downregulate ghrelin synthesis in the stomach
and subsequentlyneuropeptide-Yinthe hypothalamus, with
ultimately the same eﬀect of appetite suppression [18–
21].
Finally, and very much in keeping with the favorable
metabolic eﬀects listed above, we showed for the ﬁrst time
that CFE has potent antiatherogenic properties in a rodent
model. Concurrent administration with CFE in CA-fed rats
completely prevented the accumulation of lipids in the
intima of the thoracic aorta, which otherwise develops in
these animals [22]. We speculate that the antiatherogenic
eﬀects may be mediated at least in part via improved
plasma lipid proﬁles, with additional protection possibly
conferred by CFE’s antioxidant [23] and anti-inﬂammatory
[24]p r o p e r t i e s .Journal of Nutrition and Metabolism 5
Control ×10
(a)
Cafeteria diet ×10
(b)
Cafeteria + CFE 25mg/kg/day ×10
(c)
Figure 3: Antiatherogenic assay.
5.Conclusion
This small scale study suggested that Caralluma ﬁmbriata
extract showed pronounced dose-dependent appetite sup-
pressant and antiobesogenic eﬀects on a sample of rats fed
a cafeteria diet. These data, combined with existing CFE
clinical trial ﬁndings [13, 14], indicate that CFE has the
potential to curb obesity and the pathologies linked to
obesity.
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